Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic presents a selection of updated chapters from Re-Engineering Clinical Trials that feature innovative options and methods in clinical trials. The Coronavirus pandemic is an accelerator for digitalization in many industries, including clinical trials. This book considers best practices, alternative study concepts requiring fewer patients, studies with less patient interaction, the design of "virtualized" protocols, and moving from data to decisions. This book will be helpful to pharmacologists, physicians and clinical researchers involved in the process of clinical development and clinical trial design.

Chemoinformatics and Bioinformatics in the Pharmaceutical Sciences brings together two very important fields in pharmaceutical sciences that have been mostly seen as diverging from each other: chemoinformatics and bioinformatics. As developing drugs is an expensive and lengthy process, technology can improve the cost, efficiency and speed at which new drugs can be discovered and tested. This book presents some of the growing advancements of technology in the field of drug development and how the computational approaches explained here can reduce the financial and experimental burden of the drug discovery process. This book will be useful to pharmaceutical science researchers and students who need basic knowledge of computational techniques relevant to their projects. Bioscientists, bioinformaticians, computational scientists, and other stakeholders from industry and academia will also find this book helpful.

Practical Biostatistics: A Step-by-Step Approach for Evidence-Based Medicine, Second Edition presents a complete resource of biostatistical knowledge meant for health sciences students, researchers and health care professionals. The book's content covers the investigator's hypothesis, collective health, observational studies, the biostatistics of intervention studies, clinical trials and additional concepts. Chapters are written in a didactic way, making them easier to comprehend by readers with little or no background on statistics. Evidence-based medicine aims to apply the best available evidence gained from the scientific method to medical decision-making using statistical analyses of scientific methods and outcomes to drive further experimentation and diagnosis. With a detailed outline of implementation steps complemented by a review of important topics, this book can be used as a quick reference or hands-on guide on how to effectively incorporate biostatistics in clinical trials and research projects.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
This volume is essential for internal medicine physicians and general practitioners who prescribe antibiotic drugs, like penicillin and tetracycline that cure bacterial infections, and antiviral drugs used to treat patients with HIV and herpes viruses.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only antimicrobial drugs, but also all other drugs that act in an anti-microbial manner
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

*Presents the latest research in the field of drug discovery *Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics.

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

*Presents the latest research in the field of drug discovery *Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician.

Each year, heart disease kills more people than cancer. Patients are treated by a variety of specialists and primary care practitioners, depending on the organ system involved. This volume enables practitioners to assess the adverse effects of the complete range of drugs used in cardiovascular medicine, including antihypertensive drugs, and drugs used in the treatment of heart failure, angina, angina pectoris, and cardiac arrhythmia and enable practitioners to prescribe preventative treatments with medications such as blood pressure reducers, aspirin, and cholesterol-lowering drugs, as well as drugs used for more aggressive therapy.

The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names have been used. In some cases, brand names have been used.

This volume is critical for any health professional involved in the administration of cardiovascular mediations.
Surpasses the Physician s Desk Reference (c) by including clinical case studies and independent expert analysisComplete index of drug namesMost complete cross referencing of drug-drug interactions availableExtensive references to primary and secondary literatureAlso includes information on adverse effects in pregnancy

The book is divided into six sections:

Drugs used to treat hypertension, heart failure and angina pectorisDiuretics - a general introduction to their adverse effects, followed by monographs on individual drugsAntidysrhythmic drugs - a general introduction to their adverse effects, followed by monographs on individual drugsDrugs that act on the cerebral and peripheral circulationsAnticoagulants, thrombolytic agents, and anti-platelet drugsCardiovascular adverse effects of non-cardiovascular drugs "

Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications offers in-depth coverage on the use of molecular docking for drug design. The book is divided into three main sections that cover basic techniques, tools, web servers and applications. It is an essential reference for students and researchers involved in drug design and discovery.

"Meyler's Side Effects of Herbal Medicines," named to Doody's Core Titles for 2013, is a derivatrive work based onthe acclaimed "Meyler s Side Effect of Drugs, Fifteenth Edition." This book summarizes the adverse effects of a large range of herbal medicines and the active ingredients that they contain. It includes extensive lists of the families of plants that are used as herbal medicines, including the Latin names of genera and species as well as the common names of individual plants. It features not only herbal medicines but information on important compounds such as tropane alkaloids, cardiac glycosides, nicotine, and pyrolizidine alkaloids.

The book is divided into three separate sections: Family - Each monograph is organized under a family of plants (for example, Liliaceae) Genera - The various genera that are included under the family name are tabulated (for example, the family Liliaceae contains 94 genera) Species - In each monograph, some species are dealt with separately (for example, in Liliaceae, four species are included under their Latin names and major common names)

Each monograph includes the following information: Alternative common names Active ingredients Uses - both traditional and modern Adverse effects References

Drug names are designated by their recommended or proposed International Non-proprietary Names (rINN or pINN); when those are not available, clinical names or brand names are used.

The material is drawn from the fifteenth edition of the internationally renowned encyclopedia, "Meyler s Side Effects of Drugs, " and the latest volumes in the companion series, "Side Effects of Drugs Annuals."

This volume is critical for any health professional or homeopathic practitioner with an interest in herbal medicines.
Named to Doody s Core Titles 2013, a collection development tool for health sciences libraries of all sizes, by Doody EnterprisesSurpasses the Physician s Desk Reference (c) by including clinical case studies and independent expert analysis Complete index of drug names Most complete cross referencing of drug-drug interactions available"